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The goal of our study was to evaluate and compare the effects of receptor blockade with different endothelin (ET) receptor antagonists on plasma 
concentrations of ET-l, big ET-l and ET-3 in conscious rats. Ro 462005 (10 mg/kg, i.v.), a novel non-peptide antagonist of both ET, and ET, 
receptors, increased the concentrations of ET-l in plasma to 200 f 13% of basal levels (P 4 0.001). This effect was dose- and time-dependent and 
reached a maximum at 15 min. Ro 46-2005 had no effect on plasma concentrations of big ET-l and only a minor effect on those of ET-3. In contrast 
to Ro 46-2005, the selective peptide ET, antagonists BQ-123 and FR-139317 had no effect on plasma ET-l concentrations. The increase in plasma 
ET-l concentrations by Ro 46-2005 was most likely not due to de novo synthesis, since big ET-l levels were not increased and peak levels were 
reached early after compound injection, but perhaps to displacement of ET-l from the ET, receptors. 
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1. INTRODUCTION 
The endothelins (ET-l, ET-2 and ET-3) are a family 
of locally acting 21-amino acid peptides with potent 
vasoconstrictor activities [1,2]. The three mature pep- 
tides, ET-l, ET-2 and ET-3 are derived by enzymatic 
cleavage of their respective precursor polypeptides, the 
big endothelins, at position 21 by a putative ‘endothelin 
converting enzyme’ [3]. ET-l, ET-2 and ET-3 differ with 
respect to their binding affinities towards the two de- 
scribed endothelin receptor subtypes ET, and ET, [4,5]. 
The peptides ET-l, big ET-1 and ET-3 are present in 
low concentrations in plasma [6,7]. So far it is unclear 
whether the endothelin detected in plasma has physio- 
logical functions by its own [8] or whether the endothe- 
lin plasma concentrations reflect only a spillover of en- 
dothelin which did not bind to tissue receptor sites [9]. 
The goal of our study was to evaluate and compare the 
effects of ET-receptor blockade with Ro 46-2005, a 
novel non-peptide ndothelin receptor antagonist which 
binds to both ET, and ET, receptors [lo] and with 
BQ-123 [ll] and FR-139317 [12], two peptidic ET, se- 
lective receptor antagonists, on the plasma concentra- 
tions of endothelins. 
2. MATERIALS AND METHODS 
The ‘251-labeled ndothelins were purchased from Anawa (Wangen, 
Switzerland). BQ-123 was synthesized by A. Trzeciak at EHoffmann- 
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La Roche Ltd. (Basel, Switzerland) and FR-139317 by Neosystem 
S.A. (Strasbourg, France). Ro 462005 was dissolved in 0.9% (w/v) 
NaCl. BQ-123 and FR-139317 were solved in 0.9% (w/v) NaCl con- 
taining 30% (v/v) DMSO. 
Wistar rats were instrumented under evipan anesthesia (100 mg/kg. 
i.p.) with catheters inserted in one carotid artery and one jugular vein. 
Three hours later either the antagonists or solvent were administered 
by intravenous bolus injection. Arterial blood samples (1 ml, hepar- 
inized) were taken 5 min before and up to 240 min after intravenous 
injection. Blood samples were chilled immediately to 4°C plasma was 
separated and stored at -20°C until endothelin measurement. Im- 
munoreactive ET-l and big ET-l were measured after SepPak extrac- 
tion by specific radio immunoassays as described recently [6] except 
that the detergent Tween-20 was omitted in the assay buffer system. 
Immunoreactive ET-3 was measured as described for ET-l [6] using 
the ET-3 specific rabbit antiserum RAS 6911 at a final dilution of 
1:30,000 (Peninsula Laboratories, Merseyside, England). 
Plasma concentrations of immunoreactive ndothelins were nor- 
malized to the basal levels measured 5 min before intravenous injec- 
tion of either compound or solvent. Data are given as mean f S.E.M. 
Statistical differences were analyzed by unpaired two-tailed Student’s 
t-test. A P value < 0.05 was considered significant. 
3. RESULTS 
Normal concentrations of immunoreactive ET- 1, big 
ET-l and ET-3 were 20.0 & 0.4 pg/ml, 182.5 + 3.6 pg/ml 
and 35.6 ? 1.2 pg/ml of plasma, respectively (n = 45 per 
parameter, respectively). Ro 462005 increased plasma 
concentrations of immunoreactive ET-1 in a dose- and 
time-dependent manner. The ET- 1 plasma concentra- 
tions were maximally elevated at 15 min and remained 
significantly increased up to 240 min after compound 
injection (Fig. 1). At 10 mg/kg (i.v.) Ro 462005 in- 
creased plasma concentrations of ET-l to 200 + 13% of 
basal levels (Fig. 2). The ET-l plasma concentrations 
did not reach a plateau at this concentration. The 
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Fig. 1. Time dependency of the changes in ET-I plasma con~ntrat~ons 
after iv. administration of either solvent or 10 mg/kg Ro 46-2005. 
ET-l concentrations are expressed as percent of basal concentrations. 
n = 9; **PC 0.005, ***P < 0.001. 
plasma con~ntrations of ET-3 were also slightly ele- 
vated by Ro 46-2005 (Fig. 3). In contrast, the plasma 
concentration of big ET-l was not affected in the pres- 
ence of Ro 46-2005 (Fig. 4). Surprisingly, the selective 
peptide ET, antagonists BQ- 123 and FR-1393 17 had 
no effect on the concentrations of ET-1 in plasma 
(Table I). 
4. DISCUSSION 
Our study shows that Ro 46-2005 increases plasma 
levels of ET-l and to a lesser extent those of ET-3. A 
similar effect on circulating angiotensin II levels has 
been described for the non peptide angiotensin II recep- 
tor antagonist losartan [13,14]. The intravenous doses 
of Ro 462005 (3 and 10 mg/kg) are effective pharma- 
cological doses [lo] and led to a two-fold increase in 
circulating ET-1 concen~ations. Comparatively, block- 
ade of angiotensin II (AT 1) receptors by pharmacologi- 
cal doses of losartan led to a 17-fold increase in angio- 
tensin II levels [13]. The latter increase was most likely 
due to increased plasma renin activity and positive feed- 
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Fig. 2. Dose dependency of the effect of Ro 462005 on plasma ET-l Fig. 3. Relative changes of ET-3 plasma concentrations after i.v. 
concentrations 15 min after compound administration. ET-1 concen- administration of either solvent or 10 mg/kg Ro 462005. ET-1 con- 
trations are expressed as percent of basal concentrations. centrations are expressed as percent of basal concentrations. n = 6, 
***P<o.ool. *P < 0.05. 
Table I 
Concentrations of immunoreactive ET-l 15 min after i.v. bolus injec- 
tion of BQ-123 of FR-139317 
ET-l 
(percent of basal concentrations) 
Solvent Compound 
BQ-123 
(IO mglkg i.v.) 
FR-139317 
(10 ma&s Lv.) 
101.1 r 8.1 107.4 + 5.7 
109.5 k 15.2 113.4 i: 15.0 
Values are expressed as percent of basal ET-1 con~ntrations (n = 6, 
respectively). 
back on the synthesis of angiotensin II (1131 and refs. 
therein). In the case of increased plasma ET-l concen- 
trations by Ro 46-2005 (i) big ET-l concentrations were 
not increased, and (ii) peak elevations were already 
reached at an early time point after compound admini- 
stration. This suggests that the increase in ET-l concen- 
trations by Ro 46-2005 was not due to de novo synthe- 
sis. In contrast such an early burst could be due to 
release of ET- 1 from storage compartments or from ET 
receptors. 
In order to evaluate the receptor subtypes potentially 
involved in this ET increase, we used the selective ET, 
receptor antagonists BQ123 and FR 1393 17 at pharma- 
cologically active doses. No increase of plasma ET-l 
and ET-3 (data not shown) concentrations was ob- 
served, suggesting that Ro 46-2005, a mixed antagonist, 
increases ET levels via an action on ET, receptors. This 
seemed to be confirmed by the observation that also 
ET-3 plasma levels were elevated by Ro 46-2005, al- 
though to a much lesser extent as compared to ET-l. 
This suggests that ET is displaced from the ET, recep- 
tors of the endothelial cell layer, exposed to the luminal 
side of the vascular system. Thus, the elevated ET 
plasma levels would be a direct consequence of the com- 
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Fig. 4. Relative changes of big ET-l plasma concentrations after i-v. 
administration of either solvent or 10 mg/kg Ro 46-2005. ET-1 con- 
centrations are expressed as percent of basal concentrations. n = 6. 
petitive interaction of Ro 46-2005 with the luminal, e.g. 
exposed, ET, receptors. This would also indicate basal 
occupation of ETB receptors by ET-l. The ET, selective 
antagonists BQ-123 and FR-139317 could not increase 
ET-1 plasma concentrations, either because ETA antag- 
onism does not lead to ET-l release, or because the 
ET-I release is delayed. From the measurements per- 
formed in this study we cannot exclude that the ETA 
selective antagonists also produce elevated plasma ET-1 
levels at a later time point, i.e. after passing the endothe- 
lial cell layer which carries predominantly ETB recep- 
tors [15], and interacting with ET, receptors on smooth 
muscle cells. 
The increase of circulating ET-l concentrations by 
Ro 462005 might have physiological consequences. 
Recently, it could be demonstrated that even circulating 
ET-l concentrations could increase ETB dependent c- 
fos expression (Personnel communication: Dr. H. 
Tabuchi, Nippon Roche Research Center, Kamakura, 
Japan). The fact that Ro 462005 induces a mixed 
blockade of all ET receptors known so far explains the 
total absence of functional consequences of this in- 
crease. 
Finally, this increase of ET-1 plasma concentrations 
may be a useful indicator of receptor blockade in future 
clinical trials. 
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